Newtyn Partners, L.P. is Director at MERRIMACK PHARMACEUTICALS INC (MACK). They have made 5 open-market trades across 1 company since 2020, most recently 2023-01-12.
CIK 0001548707
5 open-market purchases totalling $2.0M since 2020, never a sale. Across 5 scored buys the stock is up 1.0% at ninety days, and 0.3 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| MACK | 1,119,586 | $16.9M |
Shares reported on the most recent Form 4, priced at the 2023-01-17 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 60% | 60% |
| Avg Move | +18.9% | +9.4% | +1.0% |
| Alpha | +17.0% | +5.5% | +0.3% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MACK | BUY | 2023-01-12 | 2023-01-17 | $11.90 | $1.2M | -6.6% | -5.1% | +4.2% |
| MACK | BUY | 2022-07-11 | 2022-07-13 | $5.88 | $21K | -11.6% | -28.0% | -46.9% |
| MACK | BUY | 2022-06-14 | 2022-06-16 | $5.19 | $186K | +2.9% | +4.2% | -25.0% |
| MACK | BUY | 2022-01-28 | 2022-02-01 | $4.51 | $116K | +3.3% | +7.9% | +0.2% |
| MACK | BUY | 2020-11-24 | 2020-11-27 | $3.65 | $504K | +106.5% | +67.8% | +72.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.